You are here

generics

J&J beats back Viatris' generic challenge to schizophrenia med Invega Trinza

J&J beats back Viatris' generic challenge to schizophrenia med Invega Trinza

Fierce Pharma

Flag link:

Drug Shortages Near an All-Time High, Leading to Rationing

Drug Shortages Near an All-Time High, Leading to Rationing

NY Times, NY

Flag link:

Novartis brings on 8 business vets for Sandoz's new board, including 4 women

Novartis brings on 8 business vets for Sandoz's new board, including 4 women

Fierce Pharma

women executives

Flag link:

SCOTUS Kills Hope for Eligibility Certainty and Nixes Teva’s ‘Skinny Label’ Appeal

SCOTUS Kills Hope for Eligibility Certainty and Nixes Teva’s ‘Skinny Label’ Appeal

IP Watchdog

Teva Pharmaceutical

Flag link:

Senate health committee seeks to rein in drug prices with four new bills

Senate health committee seeks to rein in drug prices with four new bills

BioSpace

Flag link:

Novartis spruces up Sandoz—again—by bringing 6 new US generics into the fold

Novartis spruces up Sandoz—again—by bringing 6 new US generics into the fold

Fierce Pharma

Flag link:

12,000 diseases lack treatments. One doctor thinks generics could yield cures

12,000 diseases lack treatments. One doctor thinks generics could yield cures

Stat

orphan diseases

artificial intelligence

Flag link:

Sanders, Cassidy reach deal to increase access to generic prescription drugs, reform PBMs

Sanders, Cassidy reach deal to increase access to generic prescription drugs, reform PBMs

Fierce Healthcare

Flag link:

Amgen nabs appeals win against Otezla generics, blocking Sandoz and Zydus copycats until 2028

Amgen nabs appeals win against Otezla generics, blocking Sandoz and Zydus copycats until 2028

Fierce Pharma

Flag link:

Takeda hit with another pay-for-delay lawsuit, this time on gout drug Colcrys

Takeda hit with another pay-for-delay lawsuit, this time on gout drug Colcrys

Fierce Pharma

Flag link:

Four Trends That Will Pop the $250 Billion Gross-to-Net Bubble—and Transform PBMs, Market Access, and Benefit Design

Four Trends That Will Pop the $250 Billion Gross-to-Net Bubble—and Transform PBMs, Market Access, and Benefit Design

Drug Channels

Flag link:

Biogen gets EU court ruling in favor of blocking Tecfidera generic entry

Biogen gets EU court ruling in favor of blocking Tecfidera generic entry

Seeking Alpha

multiple sclerosis

Flag link:

Jazz loses appeal, will have patent delisted from the Orange Book

Jazz loses appeal, will have patent delisted from the Orange Book

Endpoints

Flag link:

Dr. Reddy's to buy Mayne Pharma’s US generics drug list for at least $90M

Dr. Reddy's to buy Mayne Pharma’s US generics drug list for at least $90M

Endpoints

Flag link:

In antitrust suit, Hikma says Amarin locked up exclusive supply deals to shut out Vascepa generics

In antitrust suit, Hikma says Amarin locked up exclusive supply deals to shut out Vascepa generics

Fierce Pharma

Flag link:

Sun Pharma issues recall for more than 34,000 bottles of blood pressure medication

Sun Pharma issues recall for more than 34,000 bottles of blood pressure medication

Endpoints

product recalls

Flag link:

Sandoz signs deal for antifungal from Astellas in buff-up of anti-infectives portfolio

Sandoz signs deal for antifungal from Astellas in buff-up of anti-infectives portfolio

Endpoints

Flag link:

Novartis petitions Supreme Court in effort to 'vigorously defend' Gilenya patent

Novartis petitions Supreme Court in effort to 'vigorously defend' Gilenya patent

Endpoints

multiple sclerosis

Flag link:

Jazz sues generics makers for infringement on cannabis-derived epilepsy drug

Jazz sues generics makers for infringement on cannabis-derived epilepsy drug

Fierce Pharma

Flag link:

Novartis to pay $245 mln to end antitrust cases over Exforge drug generics

Novartis to pay $245 mln to end antitrust cases over Exforge drug generics

Reuters

Flag link:

Pages